AdvaMed’s “Competitiveness Agenda” proposes six changes to help make the industry more competitive, including improved early-stage R&D, more efficient and predictable FDA regulation, adequate reimbursement, fair access to foreign markets and changes in tax policies.
In supplemental comments, AdvaMed asked the IRS to make sure drug-device combination products are not made to pay both an excise tax and a prescription drug fee. The group also asked to exempt companies that build certain prepackaged surgical kits from extra taxes, arguing that such kits should not be considered a manufacturing activity in itself.
Read the release from AdvaMed.
Related Articles on AdvaMed:
AdvaMed Unveils Policy Recommendations Aimed at Protecting U.S. Medical Innovation
Medical Device Lobby Calls for 6 Changes in Federal Policy
Study: No Safety Benefit Recognized From Slower, Burdensome FDA Approval Process for Devices
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.